 Anti-thrombogenic, anti-microbial compositions containing heparin |
| OF THE INVENTION The compositions of the present invention are first dissolved in solvent mixtures ... |
|
| Derivative-compound-conjugates and pharmaceutical compositions comprising same |
| OF THE INVENTION The introduction of molecules of diagnostic, prophylactic, or therapeutic ... |
|
| Vincamine derivatives and process for the preparation of vincamine and derivatives thereof |
| Having now described our invention what we claim as new and desire to secure by Letters Patent is: 1... |
|
| Naphthyridine derivatives and their use as anti-bacterials |
| What we claim is: 1. A 1,8-naphthyridine compound of the formula ##STR9## wherein R is vinyl or 2-... |
|
| Indole derivatives |
| We claim: 1. A compound of formula (I) ##STR11## wherein R.sup.1 and R.sup.2 each represents a ... |
|
| 4-(3-(4-Quinolyl)propyl)piperidines, their preparation and their use as medicines |
| What is claimed is: 1. A method for the treatment of a mammal afflicted with a disturbance in the ... |
|
| 1,2,4-Triazoles |
| What is claimed is: 1. A compound of the formula: ##STR5## and non-toxic salts thereof, wherein R.... |
|
| Combating pests with substituted 3,6-diphenyl-3,4-dihydro-2H-1,3,5-oxadiazine-2,4-diones |
| What is claimed is: 1. An oxadiazine derivative of the formula ##STR8## in which R.sup.1 represents ... |
|
| 3-(1-Imidazolyl)-derivatives of 2,3-dihydro-4H-1-benzopyran |
| We claim: 1. Compounds having the general formula (I) ##STR89## wherein R is C.sub.1 -C.sub.6 alkyl;... |
|
|
In situ active compound assembly
| Details |
Inventors: Rideout, Darryl C.;
Assignee: Scripps Clinic and Research Foundation (La Jolla, CA)
Primary Examiner: Rollins; John W.
Assistant Examiner:
Attorney, Agent or Firm: Irell & Manella
Differences in microenvironments associated with various cells and other conditions in this environment are used to advantage in effecting the in situ construction of biologically active agents at target locations in preference to surroundings which are desired to be unaffected. |
|
DETAILED DESCRIPTION I claim: 1.
A method to modify a target condition contained within an environment with a conjugate active in modifying said target condition which conjugate comprises at least two components which method comprises providing said environment with said components, which may be the same or different wherein said components become covalently bonded to obtain the conjugate active in modifying said target condition when in the microenvironment of the target condition.
2.
The method of claim 1 which is effective to localize selectively the effect of said conjugate on said target condition.
3.
The method of claim 2 wherein the selective localization is achieved by accessibility of the microenvironment to the components as compared to the conjugate combined with ability of the microenvironment to prevent the release of the conjugate.
4.
The method of claim 1 wherein said components selectively become covalently conjugated to obtain the conjugate in the microenvironment of the target condition.
5.
The method of claim 4 wherein at least one of the components is selectively concentrated in the microenvironment of the target condition.
6.
The method of claim 5 wherein the selective concentration is achieved by the microenvironment being preferentially attractive to said component.
7.
The method of claim 6 wherein the microenvironment comprises tumor cells.
8.
The method of claim 7 wherein at least one component contains a residue selected from the group consisting of rhodamine, uroporphyrin, and hematoporphyrin.
9.
The method of claim 5 wherein the selective concentration is achieved by the microenvironment being capable of binding covalently to said component.
10.
The method of claim 5 wherein the selective concentration is achieved by the microenvironment being differentially capable of activating said component.
11.
The method of claim 5 wherein the selective concentration is achieved by the microenvironment being differentially incapable of inactivating said component.
12.
The method of claim 4 wherein the microenvironment of the target condition is differentially favorable for the covalent bonding of the components to form said conjugate
|
| Related patents |
|
|
Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
The invention is directed to a method for the prophylaxis or treatment of an animal for systemic hypotension or other pathogenic syndromes induced by inappropriate ...
|
|
|
Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier ...
|
|
|
Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
The inventors herein propose uses of anti-TNF antibodies, anti-endotoxin antibodies, and cytokine receptor antagonists (e.g., IL-1 receptor antagonist) in combination ...
|
|
|
Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor
We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.dbd.X)NHY wherein X is O, S or NH; and Y is hydrogen, hydroxy, alkyl ...
|
|
|
Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations
What is claimed is: 1. A pharmaceutical composition comprising in a vehicle suitable for enteral, parenteral, topical or ocular administration, at least one aromatic ...
|
|
|
Antioxidant-induced apoptosis in vascular smooth muscle cells
The invention is based on the discovery that, unlike other cell types, vascular smooth muscle cells which contribute to the development of arteriosclerosis are induced ...
|
|
|
Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
In a method aspect, this invention relates to a method of treating the climacterium symptoms in a non-pregnant female or in a male mammal which comprises administering ...
|
|
|
Microbial hair tonic composition
We claim: 1. A microbial hair treatment composition comprising 10.sup.6 to 10.sup.8 cells/ml of cultured living Staphylococcus capitis and a suitable solvent. 2. The ...
|
|
|
Hair treating composition
OF THE INVENTION The formulation of 9 parts d-panthenyl ethyl ether and 1 part d-panthenol can be incorporated in hair conditioning or treating compositions in an ...
|
|
|
Hair cosmetic composition
We claim: 1. A composition of matter in the form of a solution, comprising: (a) a solvent including ethanol; (b) a hair-growing component which is at least one compound ...
|
|
|
Vasodialators 
